CTLA-4 (CD152): A versatile receptor for immune-based therapy.
Sign Up to like & getrecommendations! Published in 2019 at "Seminars in immunology"
DOI: 10.1016/j.smim.2019.101298
Abstract: Coreceptor-based immunotherapy is a rapidly developing approach to treat cancer patients. Among those targeted receptors, CTLA-4 is the primary attenuator of adaptive immune responses and the most prominent and extensively investigated molecule in this field.… read more here.
Keywords: immune; ctla cd152; versatile receptor; cd152 versatile ... See more keywords